SCHEMBL1110187

SCHEMBL1110187

CCCCC(C(=O)O)N(c1cccc2c(NC(=O)Cc3ccccc3OC)cccc12)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.45
KDM4E B2RXH2 3/20 0.45
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
LPAR1 Q92633 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1318949 0.88 KCNQ2 (0.42) GAAKDM4ELMNAALDH1A1HPGD
SCHEMBL1110205 0.87 CA12 (0.42) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1110472 0.87 POLB (0.47) GAAKDM4ELMNAMEN1KMT2A
SCHEMBL1110284 0.84 PSEN1 (0.42) GAAKDM4ELMNATSHRMAPT
SCHEMBL1110213 0.84 KDM4E (0.42) GAAKDM4EMEN1KMT2AMAPT
SCHEMBL1110297 0.83 CA12 (0.41) KDM4ELMNAMEN1KMT2ATSHR
SCHEMBL1110408 0.83 GAA (0.50) GAAKDM4ELMNAMEN1KMT2A
SCHEMBL1110475 0.83 MAPT (0.38) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL1319294 0.79 KDM4C (0.38) LMNAMEN1KMT2AMAPTALDH1A1
SCHEMBL1110368 0.78 PSEN1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 GAA 204/4885KDM4E 1402/4885LMNA 3223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.